Lidia Delgado1, Gloria Jurado2, Gema Galayo2, Elena Ogalla2, Lourdes Moreno3, Juan C Rodríguez-Aguilera4, Isabel Velasco5, Sergio Varo5, Ángel Cebolla5, Miguel Arévalo-Rodríguez5, Alba Muñoz-Suano5, Carolina Sousa3, María Flores2 and Sebastián Chávez1.
1Department of Genetics, Universidad de Sevilla, Seville, Spain. 2Ingeniatrics Tecnologías SL, Spain. 3Department of Microbiology and Parasitology, Universidad de Sevilla, Seville, Spain. 4Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide, Seville, Spain. 5Biomedal SL, Spain.


Classical procedures for microbial detection and characterization involve colony isolation and can thereby be impractical when fast analysis of growth is required, or when applied to organisms that are refractory to axenic cultivation when extracted from their natural environments. To overcome these drawbacks, new technologies based on single-cell encapsulation have been developed that facilitate isolation and analysis of microscopic colonies. In addition, these technologies can speed up assessment of antibiotic resistance/sensitivity in clinical isolates of infectious bacteria, and therefore accelerate decision making on patient treatment. In this work, we have successfully tested the Flow Focusing® encapsulation technology applied to a variety of organisms, and monitored cell viability and proliferation by flow cytometry.

To read the complete Poster, please click Here



TFIIS is required for the balanced expression of the genes encoding ribosomal components under transcriptional stress. Researches utilized Cellena.


Fernando Gómez-Herreros, Lola de Miguel-Jiménez, Macarena Morillo-Huesca, Lidia Delgado-Ramos, María C. Muñoz-Centeno and Sebastián Chávez*
Departamento de Genética, Facultad de Biología, Universidad de Sevilla, Avda Reina Mercedes 6. E-41012 Seville, Spain
Received February 18, 2011; Revised April 4, 2012; Accepted April 5, 2012

Transcription factor IIS (TFIIS) stimulates RNA cleavage by RNA polymerase II by allowing backtracked enzymes to resume transcription elongation.
Yeast cells do not require TFIIS for viability, unless ,they suffer severe transcriptional stress due to NTP-depleting drugs

like 6-azauracil ormycophenolic acid. In order to broaden our knowledge on the role of TFIIS under transcriptional stress, we carried out a genetic screening for suppressors of TFIIS-lacking cells’ sensitivity to 6-azauracil and mycophenolic acid. Five suppressors were identified, four of which were related to the transcriptional regulation of those genes encoding ribosomal components [rRNAs and ribosomal proteins (RP)], including global regulator SFP1. This led us to discover that RNA polymerase II
is hypersensitive to the absence of TFIIS under NTP iscarcity conditions when transcribing RP genes. The absence of Sfp1 led to a profound alteration of the transcriptional response to NTP-depletion, thus allowing the expression of RP genes to resist these
stressful conditions in the absence of TFIIS. We discuss the effect of transcriptional stress on ribosome biogenesis and propose that TFIIS contributes to prevent a transcriptional imbalance between rDNA and RP gene.


Read the complete paper here




Biomedal and Ingeniatrics signs a distribution agreement for Cellena® bioencapsulator.


Dr. Angel Cebolla Ramirez and Mr. Joaquin Gómez Moya

Biomedal SL and Ingeniatrics have signed a strategic distribution agreement. Biomedal will be the global distributor of Ingeniatric's portable Bioencapsulation device, Cellena®. The agreement was signed on Friday, March 16th at Ingeniatrics’s facilities by both companies CEOs Dr. Angel Cebolla Ramirez, Biomedal, and Mr. Joaquin Gómez Moya, Ingeniatrics.


Cellena® is a user-friendly, portable device that makes unneeded the use of autoclave as it is provided with sterile disposable nozzles. Nonetheless it is aimed to a highly specialized market: e.g. stem cells researchers; it is a complex sales process that requires a distributor like Biomedal. This is a well known biotechnology company with a seasoned sales force and whose mission is to develop and commercialize new biomedical technologies, services and products for research, bioindustry and diagnostics. Biomedal enhances the talent of its team with the collaboration of an outstanding and growing network of international scientists and technologists, and directs its efforts to satisfy its customers.

The excellent market position of this company based in Seville ensures short-term success in Emerging markets as cell therapy or stem cell research

Bioencapsulation Step forward

“This agreement confirms the Ingeniatrics effort  to settle down as one of the main microencapsulation key-players. Cellena® would improve some assays and diagnostics in an order of magnitude and can be utilized in combination with cytometers like - for instance - COPAS and Biosorter” indicated Ángel Cebolla.

Biomedal will offer this device among other products to improve the society quality of life and has started proposing Bioencapsulation as a cost-effective solution to the some of the most important research groups in the world. On the other hand, Ingeniatrics still owns the Flow Focusing® technology and stays sole manufacturer of Cellena®.

For further information please click here



AENOR certificates Ingeniatrics' Quality Control and Environment management according to ISO 9001 and 14001.

Lola Romero Guzmán, Ingeniatrics's QA & Environment Manager.


On March 2012, the technological company Ingeniatrics, specialized in design and production of micro and nano particles and the equipment to produce them, has attained ISO 9001 and ISO 14001 certificates issued by AENOR, acknowledging that Ingeniatrics’ environmental and quality management systems fully meet international requirements according to UNE-EN-ISO 9001:2008 and UNE-EN-ISO 14001:2004 after the corresponding audits.




The audit was carried out by a team of AENOR, Asociación Española de Normalización y Acreditación, which is in possession of close to 190 national and international accreditations including ENAC's. ENAC is the Spanish Accreditation Body which in turns belongs the international quality certification accreditation system and is recognized in the UE, EFTA, USA, Canada, Japan, China, Australia... Up to 60 countries.


Continuous improvement in the long run:


Pilot plant’s construction ended in December 2011, so validation tests, operational and procedures qualification started up immediately after that. Simultaneously quality control projects had started on March 2011, going through different phases of study, project, documentation, procedures definition, procedures deployment, reviews, mandatory pre-auditory and finally - on December 2011 and January 2012 - the audit itself.  

Ingeniatrics' quality control and environmental management was led by Lola Romero who indicates “this milestone is not the end, but the beginning of a way of continuous improvement which reaffirms the company position in the market”. Ingeniatrics' principals have targeted chemical, pharmaceutical and food major corporations interested in the applications of Flow Focusing and Flow Blurring microparticles technology.




Certification for pharma field is in progress. Current certificate scope is: "Provision of microencapsulation services for Chemicals and Nutrition industries. Design and manufacturing of micro- and nano- particles. Design and manufacturing of nebulizers and atomization systems."


Ingeniatrics and Aradigm sign a licensing agreement to apply Flow Focusing® and Flow Blurring® technology to inhalation drugs.


The technological Ingeniatrics and Aradigm, a pulmonary pharmaceutical industry pioneer, signed a new agreement in February, 2012. By this, Aradigm is licensed by Ingeniatrics to develop and operate in the field of medicaments administration to or through respiratory tract using flow focusing and flow blurring technology. 


Aradigm's multidisciplinary team led by Dr. Igor Gonda and David Cipolla has experience at developing a variety of pharmaceutical and health care products and launching them to the market.

Aradigm gets an exclusive, world-wide license on Ingeniatrics's technology to develop, make, use, sell, and  offer for sale drugs delivered by inhalation, including drugs for  severe respiratory disease treatment.

Enhanced Licensees support:

Once Ingeniatrics had reached agreements with Flow Pharma and the University of Seville, this agreement with Aradigm confirms Ingeniatrics’ control and strengthen its position. Due to this, the microencapsulation company offers a stable, safe and simplified framework to all its licensees and their sub- licensees in order to ensure their business model.



Optimized Intellectual Property management:


Ingeniatrics is currently focused on scaling its technologies up, enhancing its capacity to offer services and products making use of its brand-new three hundred square meters microencapsulation pilot-plant, which is made up of three separate rooms for Pharma (registered as "cleanroom" or ISO 7 white room), Food and Chemistry.

By virtue of this agreement, Ingeniatrics will be the only Flow Focusing® and Flow Blurring® patents manager world-wide. Alongside with other previous agreements, this one grants to Ingeniatrics a solid base to strategize the best course of action to protect its microencapsulation and nebulization Intellectual Property.




The present study led by Dr. Jose Luis Pedraz's research group (University of Vitoria) covers a comprehensive technological development introducing the Ingeniatrics's Flow Focusing System® as a promising technique to obtain highly monodisperse 100 μm alginatepoly-L-lysine-alginate (APA) microcapsules. These preliminary results open the door to further investigations, where the effectiveness of this technology might be tested in a retinopathy model.


The field of cell microencapsulation is advancing rapidly. Particle size plays a critical role in terms of biocompatibility and limits decisively its applicability. Producing reduced size microcapsules involves broadening the possibilities to employ this technology in the treatment of many disorders. Nervous system diseases (NSD) represent a clear example of that.


Please, click here to read the entire paper



New dimension of possibilities


Our scalability opens a new dimension of possibilities and increases our microparticles production and its versatility in order to satisfy costumers needs thanks to our own Flow Focusing®  Spray Drying with multiplexed nozzle-head system.

Now its enable scaled up process definition. Due to its precision, stability, continuity, repeatability new development and validation systems is possible

What is your need? Please challenge us!

Click below for further information:

- Time to update your ideas on Microencapsulation

- Scaleable Flow Focusing Microencapsulation



A quick spec on Ingeniatrics latest achievements

Ingeniatrics briefly presented its technological advances, expanding product portfolio in market and increase solutions in customer needs by the new facilities' scalability in order to produce and manufacture microparticles.

For further information click here


Aliter journal: Biotechnology and business

Aliter published the fourth edition of the journal "Biotechnology and Business."  This publication aims to connect companies, government agencies, authorities, investors and universities.

In this issue we could find several interest biotechnology topics, such as interviews with sector business leaders, successful managers as  Joaquin Gomez Moya, CEO of Ingeniatrics, as well as international studies.

For further information click here


Detection and characterization of microorganisms usually involves culture during more than 20 generations in order to achieve the formation of macro colonies on solid media. Alternatively, microencapsulation allows the detection of microbial growth by monitoring the development of micro colonies from encapsulated individual cells.

Microbial proliferation inside the microcapsules can be detected using COPAS™ (Union Biometrica platform designed for the measurement of objects ranging in size from 20–1500 microns (diameter).) large particle flow cytometry without requiring fluorescent labeling.


See the poster

From Ingeniatrics we are very proud of the impact achieved with our presentation on the Internet. If you want to download and share click  here

Please find information about the p
rogress, joint venture, IP, venture capital round, brand-new facilities, Frost&Sullivan award, GMP manufacturing plants, own spry-dryer system, cleanroom, CRO and CMO services or products already marketed.


Ingeniatrics received last September 29th in London the Technology Innovation Award. Ingeniatrics Tecnologias CEO Joaquin Gomez’s words have been: "We are delighted and honored to representIngeniatrics in an event so distinguished"


Ingeniatrics’ R&D Director María Flores has published an article in Bioencapsulation Innovation about Flow Focusing® Microencapsulation by means of Cellena® Bio Encapsulator device. In particular, examples of the Flow Focusing® technology for the microencapsulation of different types of cells in monodis­perse hydrogel microspheres using a Cellena® Flow Focusing® microencapsulator.

To read the article click on the link below, page 16

Flores-Mosquera, M.; Jurado, G; Chávez, S.; Gañán-Calvo, A.M.


Microbial encapsulation in monodisperse hydrogel microspheres enables fast and sensitive phenotypic analyses using flow cytometers

Detection and characterization of microorganisms usually involves culture during more than 20 generations in order to achieve the formation of macrocolonies on solid media. Alternatively, microencapsulation allows the detection of microbial growth by monitoring the development of microcolonies from encapsulated individual cells. Microbial proliferation inside the microcapsules can be detected using flow cytometry, provided that the population of microparticles exhibit appropriate optical and mechanical properties and is monodisperse in size and shape.

Here we show the successful application of the Flow Focusing® technology to the microencapsulation of different types of cells in monodisperse hydrogel micropheres.

Using a CellENA® Flow Focusing® microencapsulator, we managed to produce monodisperse alginate microparticles containing individual bacteria, yeast and human stem cells. Alginate particle sizes were reproducibly selected from less than 100 µm to over 600 μm, by just replacing the disposable nozzle. Sterility was preserved during the microencapsulation procedure, preventing undesired contaminations.

Microencapsulated microorganisms were used for a variety of application: from characterizing secreted enzymes to detection of thermosensitive mutants. Proliferation inside the particles was monitored by flow cytometry without requiring fluorescent labelling.

Download PDF